Aruba vs British Virgin Islands: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Aruba
0.2%
in 2024
British Virgin Islands
0.2%
in 2024
Aruba rank
78th
British Virgin Islands rank
78th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Aruba
- British Virgin Islands
How they compare
Aruba currently reports 0.2% against 0.2% in British Virgin Islands, a difference of 0.0%.
Across all 10 years both countries report, British Virgin Islands has been ahead every year.
Aruba ranks 78th and British Virgin Islands ranks 78th of 215 countries.
Head to head by decade
| Decade | Aruba | British Virgin Islands | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | — |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Aruba or British Virgin Islands?
- Aruba, at 0.2% against 0.2% in British Virgin Islands as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Aruba and British Virgin Islands?
- 0.0%, with Aruba ahead.
- How many years of comparable data are there for Aruba and British Virgin Islands?
- 10 years are reported by both, from 2015 to 2024.
- How do Aruba and British Virgin Islands rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Aruba ranks 78th and British Virgin Islands ranks 78th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.